Back News from our Industry Partner - Bayer
We are committed to support your efforts to effectively and promptly treat cardiovascular patients in these challenging times. whether your priority is to continue transitioning eligible patients from a vitamin K antagonist (VKA) to direct oral anticoagulants (DOACs), or the continued identification and management of other at-risk patient groups.
You can find resources, including a simple guide on how to transition and counsel your eligible non-valvular atrial fibrillation (NVAF) patients from warfarin to DOAC as well as a range of patient information materials on our website.
In order to provide the latest information on our services and patient support materials, we would like to ask for your consent to engage with us digitally. Please be assured that we will only share information and online resources that are relevant to you and you can opt out of receiving communication from us at any time. Please click here to subscribe to receive electronic communications about Bayer’s products, services and events.
For prescribing information and adverse event reporting please click here.
PP-XAR-GB-1450 June 2020